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Abstract  
Topical vaginal sustained delivery of siRNA presents a significant challenge due to the short 
residence time of formulations. Therefore, a drug delivery system capable to adhere to the 
vaginal mucosa is desirable, as it could allow a prolonged delivery and increase the 
effectiveness of the therapy. The aim of this project is to develop a polymeric solid 
mucoadhesive system, loaded with lipoplexes, able to be progressively rehydrated by the 
vaginal fluids to form a hydrogel and to deliver siRNA to vaginal tissues. 
To minimize adhesive interactions with vaginal mucus components, lipoplexes were coated 
with different derivatives of polyethylene glycol: DPSE-PEG2000, DPSE-PEG750 and ceramide-
PEG2000. Based on stability and diffusion properties in simulated vaginal fluids, lipoplexes 
containing DSPE-PEG2000 were selected and incorporated in hydroxyethyl cellulose (HEC) 
hydrogels. Solid systems, called sponges, were then obtained by freeze-drying. Sponges meet 
acceptable mechanical characteristics and their hardness, deformability and mucoadhesive 
properties are not influenced by the presence of lipoplexes. Finally, mobility and stability of 
lipoplexes inside sponges rehydrated with vaginal mucus, mimicking in situ conditions, were 
evaluated by advanced fluorescence microscopy. The release rate was found to be influenced 
by the HEC concentration and consequently by the viscosity after rehydration.  
This study demonstrates the feasibility of entrapping pegylated lipoplexes into a solid matrix 
system for a prolonged delivery of siRNA into the vagina.  
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Abbreviations:  
Ceramide-PEG2000: N-octanoyl-sphingosine-1-{succinyl[methoxy(polyethylene glycol)2000]} 
DSPE-PEG2000: 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene 
glycol)-2000 
DSPE-PEG750: 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene 
glycol)-750] 
FCS: fluorescence correlation spectroscopy  
fluo-siRNA: fluorescent small interfering RNA  
fSPT: fluorescence single particle tracking 
HEC: hydroxyethyl cellulose 
PdI: polydispersity index  
PEG: polyethylene glycol 
PEG400: polyethylene glycol 400 
SEM-EDX: Scanning Electron Microscopy and Energy Dispersive X-Ray Analysis 
siRNA: small interfering RNA 
SVF: simulated vaginal fluid  
TA: texture analyser 
TAE: Tris Acetate EDTA buffer 
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1. Introduction 1 
In the context of genital diseases, the vaginal route of administration has gained great attention 2 
for drug delivery and has been extensively studied for effective delivery of different drug 3 
molecules [1-3]. Advantages over other routes of drug administration include low drug doses, 4 
reduced risk of systemic immune activation, site-specific delivery, and most importantly, 5 
circumvention of first-pass hepatic clearance [4]. The ease of administration and low toxicity 6 
profile make the vaginal route an excellent site for the delivery of many drugs and particularly 7 
for siRNA delivery for the treatment and prevention of vaginal and/or cervical diseases [5-7]. 8 
However, naked siRNAs have difficulties in achieving efficient mucosal uptake if administered 9 
directly into the vagina due to degradation, poor cellular uptake, low mucus diffusion and high 10 
clearance. In order to overcome these obstacles, siRNA need to be encapsulated in a vector, 11 
such as liposomes. 12 
Liposomes have been largely investigated as vaginal drug delivery system [8-11]. However, 13 
vaginal conditions are subject to changes because of numerous physiological and non-14 
physiological factors that can lead to variations in the bioavailability of drugs. Moreover, a 15 
vaginal administration of lipoplexes (liposomes encapsulating siRNA) encounters important 16 
barriers such as the penetration through the mucus to reach the epithelial tissue and a short 17 
residence time. One strategy to improve the particle diffusion through the mucus and to create 18 
“mucopenetrating” lipoplexes is to densely coat their surface with polyethylene glycol (PEG) 19 
[1, 12, 13]. PEG is a neutral hydrophilic polymer that has been described to minimize adhesive 20 
interactions between nanoparticles and mucus components, allowing them to penetrate rapidly 21 
through viscoelastic human mucus secretions [14, 15]. The size of the lipoplexes is also 22 
another important parameter to consider for the diffusion. It has been shown that particles with 23 
a diameter around 200 - 300 nm can diffuse more rapidly through undiluted human vaginal 24 
mucus, than smaller ones (100 nm) and bigger ones (> 500 nm) [16, 17].  25 
Unfortunately, even if lipoplexes are mucopenetrating, they have a short residence time, which 26 
conducts them to be quickly eliminated. In order to improve the vaginal retention, lipoplexes 27 
should be incorporated in an appropriate depot system with a desirable viscosity and with 28 
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mucoadhesive properties. For this purpose, a polymeric hydrogel can be a good solution [18]. 29 
Among the different mucoadhesive polymers used for vaginal administration and based on 30 
previous results [19-21], cellulosic derivatives and particularly hydroxyethyl cellulose (HEC) 31 
are attractive candidates. It has also been described that lipid vesicles are compatible with 32 
HEC hydrogels [22].  33 
Finally, in order to avoid drug degradation and to obtain a solid and easy to handle system, the 34 
hydrogels containing pegylated lipoplexes should be freeze-dried. The obtained system, called 35 
sponge, has been previously described and characterized [19].  36 
Taken together, increasing the residence time with the vaginal mucosa by introducing 37 
pegylated lipoplexes inside a mucoadhesive solid system can be crucial for efficient vaginal 38 
siRNA delivery. Combining mucoadhesion and prolonged drug delivery possesses the 39 
advantages to improve patient’s compliance and to reduce the frequency of application.  40 
Here, we develop a novel solid matrix system able to adhere to the vaginal mucosa, to be in 41 
situ rehydrated by the vaginal fluids to form a hydrogel and to deliver in a sustained manner 42 
mucopenetrating pegylated lipoplexes and consequently siRNA to vaginal tissues under 43 
pathological conditions.    44 
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2. Material and Methods 45 
 46 
2.1. Material  47 
1,2-Dioleoyl-3-trimethylammonium-propane (chloride salt) (DOTAP), 1,2-dioleoyl-sn-glycero-48 
3-phosphoethanolamine (DOPE), cholesterol, 1,2-distearoyl-sn-glycero-3-49 
phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (ammonium salt) (DSPE-50 
PEG2000), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-51 
750] (ammonium salt) (DSPE-PEG750) and N-octanoyl-sphingosine-1-52 
{succinyl[methoxy(polyethylene glycol)2000]} (ceramide-PEG2000) were purchased from Avanti 53 
Polar Lipids, Inc. (Alabaster, Alabama, USA). Scramble siRNA (siRNA) and fluorescent 54 
scramble siRNA with alexa Fluor® 647 (fluo-siRNA) were provided by Eurogentec® 55 
(Eurogentec SA, Liège, Belgium) with the following sequence: sense strand: 5’-56 
AGAGUUCAAAAGCCCUUCdTdT-3’ and antisense strand: 5’-57 
GAAGGGCUUUUGAACUCUdTdT-3’ (alexa Fluor 647 in position 5’). TAE buffer (50X pH 8.0) 58 
was obtained from VWR (Leuven, Belgium). D-(+)-trehalose dehydrate (from Saccharomyces 59 
cerevisiae, ≥ 99%) was purchased from Sigma - Aldrich (Schnelldorf, Germany). Hydroxyethyl 60 
cellulose 250M (HEC) was purchased from Ashland (Covington, USA) and polyethylene glycol 61 
400 (PEG400) was purchased from Fagron (Waregem, Belgium). All the components used to 62 
prepare synthetic vaginal mucus were purchased from Sigma - Aldrich (Schnelldorf, Germany). 63 
 64 
2.2. Lipoplexes formulations  65 
2.2.1. Preparation of lipoplexes  66 
Liposomes were prepared from a mixture of DOTAP, cholesterol and DOPE at the molar ratio 67 
1/0.75/0.5, by the hydration of lipid film method, as described previously [23]. Briefly, lipids 68 
were dissolved in chloroform at a total concentration of 5.6 mM. The organic solvent was 69 
removed using a rotary evaporator. The resulting thin lipid film was hydrated with 2 mL of 70 
RNAse free water and vigorously vortexed. Finally, the suspension was repeatedly extruded 71 
through polycarbonate membranes with 200 nm pore size.  72 
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Lipoplexes were obtained in RNAse free water by electrostatic interaction between liposomes 73 
and siRNA at the N/P ratio of 2.5 [19].  74 
Lipoplexes were pegylated by addition of 30% of DSPE-PEG2000, DSPE-PEG750 or ceramide-75 
PEG2000 (% mol / DOTAP) by the post-insertion technique. In brief, the PEG in RNAse free 76 
water (1 mM) were added to preformed lipoplexes and the resulting suspension was vortexed 77 
and maintained 1 h at 37°C under continuous stirring. 78 
 79 
2.2.2. Freeze-drying of lipoplexes 80 
Samples were prepared at 300 nM siRNA concentration in a final volume of 1 mL. Different 81 
amounts of trehalose were added (from 1 to 10% m/v) to the lipoplexes. Lipoplexes were then 82 
freeze-dried using a vacuum freeze-dryer (Heto-Holten DW 8030, Vacuubrand RZ8 pump) with 83 
a freeze-drying cycle previously described [19]. 84 
 85 
2.2.3. Particles characterization  86 
The physicochemical characteristics of the lipoplexes were evaluated before and after freeze-87 
drying. Freeze-dried lipoplexes were rehydrated with 1 mL of RNAse free water and stirred for 88 
30 min at room temperature.  89 
a. Particle size, polydispersity, zeta potential  90 
The mean diameter (nm) and the polydispersity index (PdI) of the lipoplexes (100 nM siRNA, 91 
1 mL) were determined by Dynamic Light Scattering method. The charge density was 92 
evaluated by examining the zeta potential (mV). Both measures were made at 25°C, using a 93 
Malvern Zetasizer® (Nano ZS, Malvern Instruments, UK) [23].  94 
b. Complexation efficiency 95 
The level of siRNA complexation was evaluated by agarose (4%) gel electrophoresis. In brief, 96 
lipoplexes (300 nM, 30 µL) were loaded onto the agarose gel in TAE buffer and the 97 
electrophoresis was performed at 100 V for 1 h in a Horizon 11.14 horizontal gel 98 
electrophoresis apparatus (Biometra, Goettingen, Germany). Gel was visualized by exposure 99 
to UV-illumination by a Molecular Imager Gel Doc XR System (Bio-Rad, Hercules, CA, USA). 100 
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c. Stability  101 
Freeze-dried lipoplexes were stored in closed glass vials at 4°C for 25 days. The integrity of 102 
complexed siRNA was assessed by agarose gel electrophoresis. Triton X-100 (0.5% w/v) was 103 
used to break vesicles and release the complexed siRNA [23]. Gel retardation assay was 104 
performed in the same conditions as described in section 2.2.3.b.  105 
The mean diameter, the PdI and the zeta potential of the freeze-dried lipoplexes were also 106 
measured, as described in section 2.2.3.a.  107 
 108 
2.3. Sponges formulations 109 
2.3.1. Preparation of placebo sponges 110 
Hydrogels (6 g) were prepared by gradual dispersion in water of HEC polymer (0.83% or 111 
1.67%) and PEG400 (0.41%), at room temperature and under magnetic stirring. Once 112 
homogeneous aqueous dispersions were obtained, the hydrogels were then freeze-dried to 113 
form sponges [19].  114 
 115 
2.3.2. Preparation of sponges loaded with lipoplexes 116 
HEC (0.83% or 1.67%), PEG400 (0.41%) and trehalose (1%) were gradually dispersed in 117 
lipoplexes (300 nM, 6 mL) suspension at room temperature and under magnetic stirring. The 118 
obtained hydrogels containing lipoplexes were then freeze-dried as described above.  119 
 120 
2.3.3. Preparation of artificial vaginal mucus 121 
Simulated vaginal mucus (SVF) was prepared with NaCl (0.351 g), KOH (0.140 g), Ca(OH)2 122 
(0.022 g), bovine serum albumin (0.002 g), lactic acid (0.200 g), acetic acid (0.100 g), glycerol 123 
(0.016 g), urea (0.040 g), glucose (0.500 g) and dried porcine gastric mucin (type 3) (1.5% w/v) 124 
mixed to 90 mL of milliQ water [24, 25]. SVF was stirred until complete dispersion of the 125 
components. The pH was adjusted to 6 using HCl (0.1 M) and the final volume was adjusted 126 
to 100 mL with milliQ water. 127 
 128 
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2.3.4. Characterization  129 
a. Mucoadhesion  130 
The mucoadhesive strength (N) was determined using a Texture Analyzer (TA) (Lloyd 131 
Instruments, Ametek Company) in compression mode and with hydrated mucin disc, as 132 
described previously [19, 22]. Briefly, the sponges were attached with both side adhesive tape 133 
on the table of the TA. The mucin disc fixed to the probe (13 mm diameter) was brought into 134 
contact with the sponge with a preload of 0.1 N and was maintained for 60s to ensure intimate 135 
contact. The probe was then elevated and the mucoadhesive strength was determined from 136 
the detachment force between the disc and the sponge. The mucoadhesion of different 137 
commercialized pharmaceutical products for vaginal administration (Gynodaktarin®, Lubrilan®, 138 
Mithra Intim gel®, Gynoxin®, Lubexxx®, Canestene®, Crinone®, Preventex®) was also measured 139 
in the same condition in order to compare them to prepared sponges.  140 
b. Hardness and deformability 141 
The hardness (N) and the deformability (%) of the sponges were determined with a TA in 142 
compression and cyclic mode. The sponges were attached with both side adhesive tape on 143 
the table of the TA. A cylindrical probe (25 mm diameter) was compressed four times into each 144 
sample with a preload of 0.5 N, at a defined rate (1 mm/s) and to a defined depth (0.2 mm). 145 
The hardness is the force measured after the first compression. The deformability is the ratio 146 
of the force obtained after the first compression and the force measured after each cycle.  147 
c. Scanning Electron Microscopy and Energy Dispersive X-Ray Analysis (SEM-EDX) 148 
Scanning electron microscopy (SEM) was performed on sponges loaded with lipoplexes using 149 
a Field Emission Environmental microscope (Philips, model XL 30) after metallization with 150 
platinum (30 nm). Elemental detection was also performed with this microscope without 151 
preparation of the samples. The morphology of the lipoplexes was analysed. Lipoplexes were 152 
identified by the phosphorus atom (P) of siRNA molecules.  153 
 154 
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2.4. Diffusion and colloidal stability of lipoplexes  155 
Lipoplexes were prepared with fluo-siRNA (300 nM) and the sponges were loaded with 156 
fluorescent lipoplexes, as described in sections 2.2.1. and 2.3.2. Sponges were previously 157 
rehydrated with 2 mL of SVF at 37°C in order to mimic in situ vaginal conditions before 158 
measuring the diffusion of lipoplexes. 159 
2.4.1. Fluorescence Single Particle Tracking (fSPT) 160 
For the analysis of lipoplexes inside mucus, 10 µL of lipoplexes were added to 40 µL of SVF 161 
in a 8-well plate and for the analysis of lipoplexes loaded into rehydrated sponges, 50 µL were 162 
sampled. Moreover, 10 µL of lipoplexes were added in 40 µL of RNAse free water, as a control 163 
condition. Each sample was allowed to equilibrate for 15 min at 37°C before being placed on 164 
the swept-field microscope (Nikon, Brussels, Belgium) equipped with a 60x oil immersion lens 165 
(Nikon) and with a stage top incubator kept at 37°C. Movies were recorded with NIS Elements 166 
software (Nikon) driving the Andor ixon ultra 897 camera (Belfast, UK). Analysis of the videos 167 
was performed using an house-developed particle tracking software [26].  168 
 169 
2.4.2. Fluorescence Correlation Spectroscopy (FCS)  170 
The samples were prepared in the same conditions as above (2.4.1.). They were placed in a 171 
glass-bottom 96-well plate (Greiner bio-one, Frickenhausen, Germany) and the fluorescent 172 
signal was measured respectively after 0 h, 2 h and 4 h of incubation at 37°C. FCS 173 
measurements were performed on a C1si laser scanning confocal microscope (Nikon), 174 
equipped with a time correlated single photon counting data acquisition module (Picoquant, 175 
Berlin, Germany). The laser beam was held stationary and was focused through an oil 176 
immersion objective lens (Plan Apo 60x, NA 1.2, collar rim correction, Nikon). The 647 nm 177 
laser beam of krypton-argon laser (Bio-Rad, Cheshire, UK) was used and the red fluorescence 178 
intensity fluctuations were recorded using Sympho-time (Picoquant, Berlin, Germany) for at 179 
least 60 s.  180 
 181 
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2.5. Release study  182 
The release rate of fluorescent lipoplexes from the sponges was monitored over time and 183 
determined by fSPT technique. The sponges loaded with fluorescent lipoplexes were placed 184 
on ThinCert® with 0.4 µm pores diameter (PET membrane, Greiner bio-one) in a 6-well TC 185 
plate (Cellstar, Greiner bio-one) and were rehydrated with 2 mL of SVF (figure 1). The acceptor 186 
compartment was filled with SVF (2.5 mL) and all the system was incubated at 37°C. Every 187 
hour during 6 h, 100 µL were collected and fSPT movies were recorded, as described in section 188 
2.4.1. in order to demonstrate the presence of lipoplexes in the acceptor compartment filled 189 
with SVF.  190 
 191 
 192 
 193 
Figure 1: Schematic illustration of monitoring lipoplexes release from rehydrated sponges and 194 
diffusion through the SVF mucus into the acceptor compartment by fSPT. 195 
 196 
2.6. Statistical analysis 197 
All values are expressed as the mean ± SEM. Statistical analyses were performed using 198 
GraphPad Prism® software. A p value < 0.05 was considered significant (*).    199 
12 
 
3. Results and Discussion 200 
 201 
3.1. Preparation, characterization and freeze-drying of lipoplexes  202 
3.1.1. Unpegylated lipoplexes  203 
As shown in figure 2 , the mean size of the lipoplexes before freeze-drying (A and B) is around 204 
200 nm in diameter with a low PdI (< 0.2) and a zeta potential around +50 mV. After freeze-205 
drying and rehydration with water (figure 2 C and D), the physicochemical characteristics of 206 
these lipoplexes are completely different: the size and PdI increase (> 500 nm and > 0.5 207 
respectively) and the zeta potential decreases (up to +10 mV). In order to prevent these 208 
variations, different percentages of trehalose were added. Indeed, as described by Chen et al. 209 
[27], the addition of a lyoprotectant, such as trehalose, is necessary to protect the membrane 210 
integrity of the lipoplexes during freeze-drying. It avoids a phase transition and can also 211 
improve drug retention by reducing the damages by ice crystals and inhibiting vesicles 212 
aggregation and/or fusion. It also favours the reversibility of nanoparticles rehydration after 213 
freeze-drying and the encapsulated drug protection [28-31]. Addition of increased amounts of 214 
trehalose (1 - 10%) only slightly modifies the size (~ 300 nm with 10% trehalose) and the PdI 215 
(~ 0.2) of lipoplexes (figure 2.A). However, the zeta potential decreases with increased 216 
concentration of trehalose (figure 2.B). After freeze-drying with trehalose and rehydration, 217 
lipoplexes recover their original size (~ 200 nm), particularly when small concentrations of 218 
trehalose were used (1 - 3%) (figure 2.C). Higher trehalose concentrations seem to slightly 219 
increase the size. Concerning the zeta potential, figure 2.D depicts that the surface charge 220 
decreases up to neutrality in the presence of 10% trehalose. In order to keep as close as 221 
possible the initial physicochemical characteristics of the lipoplexes, 1% of trehalose was 222 
selected for following experiments.  223 
 224 
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 225 
Figure 2: Hydrodynamic diameter (nm), PdI (A) (C) and zeta potential (mV) (B) (D) of 226 
lipoplexes with increased percentages of trehalose (1 to 10 % m/v) before and after freeze-227 
drying (n=4). 228 
 229 
3.1.2. Pegylated lipoplexes  230 
Lipoplexes were then pegylated by addition of 30% of DSPE-PEG2000, DSPE-PEG750 or 231 
ceramide-PEG2000. Indeed, it is well known that particles can easily diffuse through a mucosal 232 
vaginal layer given that they are coated with PEG [2, 32, 33]. For this reason, three different 233 
PEG derivatives were evaluated and compared. As highlights figure 3.A, lipoplexes containing 234 
DSPE-PEG2000 or ceramide-PEG2000 have the same size before (1) and after (2) freeze-drying 235 
(~ 200 nm). The PdI slightly increases but is still around 0.2. They also recover their zeta 236 
potential once rehydrated (around -10 and +20 mV respectively). Concerning the lipoplexes 237 
with DSPE-PEG750, their size increases significantly after freeze-drying (> 600 nm). The PdI 238 
also increases up to 0.4, giving rise to an increased heterogeneity of the system. However, the 239 
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zeta potential does not vary before and after freeze-drying (~ -12 mV) (figure 3.B). These 240 
results show that lipoplexes containing DSPE-PEG750 are less stable than other lipoplexes, 241 
which can be a problem for further incorporation in a prolonged release system.  242 
 243 
 244 
Figure 3: Hydrodynamic diameter (nm), PdI (A) and zeta potential (mV) (B) of lipoplexes with 245 
DSPE-PEG2000, DSPE-PEG750 or ceramide-PEG2000 and with 1% of trehalose before (1) and 246 
after (2) freeze-drying. A paired Student’s t-test is used to compare lipoplexes with DSPE-247 
PEG2000 (1)-(2), DSPE-PEG750 (1)-(2) and ceramide-PEG2000 (1)-(2) (n=6).  248 
 249 
Table 1 summarizes the physicochemical characteristics of lipoplexes before and after freeze-250 
drying. 251 
Lipoplexes Freeze-drying Diameter (nm) PdI Zeta potential (mV) 
Without PEG before after 
198,8 ± 6,1 
197,3 ± 7,4 
0,07 ± 0,01 
0,14 ± 0,02 
29,3 ± 1,9 
29,3 ± 3,9 
DSPE-PEG2000 before after 
196,1 ± 5,8 
220,6 ± 12,1 
0,15 ± 0,01 
0,25 ± 0,02 
-10,1 ± 2,1 
-10,2 ± 1,3 
DSPE-PEG750 before after 
222,0 ± 32,0 
620,9 ± 90,7 
0,15 ± 0,01 
0,40 ± 0,03 
-13,9 ± 0,6 
-10,5 ± 2,5 
Ceramide-PEG2000 
 
before 
after 
207,8 ± 3,2 
216,9 ± 6,7 
0,14 ± 0,02 
0,27 ± 0,01 
17,7 ± 1,5 
20,5 ± 2,2 
Table 1. Physicochemical characteristics of lipoplexes with 1% trehalose before and after 252 
freeze-drying. Values represent mean ± SEM (n=4). 253 
 254 
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3.1.3. Stability of freeze-dried lipoplexes 255 
The stability of the freeze-dried pegylated lipoplexes was evaluated after storage at 4°C in 256 
closed glass vials for 1 month. The mean size, the PdI and the zeta potential were measured. 257 
It appears that the size of the lipoplexes does not vary significantly and ranged between 200 258 
to 300 nm for lipoplexes with DSPE-PEG2000 and with ceramide-PEG2000. Concerning the PdI, 259 
it is generally close to 0.2 and the zeta potential remains also constant for both types of 260 
pegylated lipoplexes (data not shown).  261 
The complexation efficiency and the integrity of lipoplexes were assessed by agarose gel 262 
electrophoresis (figure 4). As shown in figure 4.A, the first two spots correspond to free siRNA 263 
(control). The three next correspond to lipoplexes with DSPE-PEG2000. Before freeze-drying, 264 
no free-siRNA is detectable. The siRNA is complexed by liposomes (1: no visible spot) 265 
confirming our previous complexation results (more than 95% of complexation [23]). The 266 
addition of trehalose does not destabilize the particles and does not release the siRNA. After 267 
freeze-drying and rehydration (spot 2), no free siRNA is visible showing that the particles form 268 
again spontaneously to almost 100%. A positive control with Triton X-100 shows that this 269 
surfactant releases all the siRNA from the lipoplexes (spot 2+Trit.), no broken and no smearing 270 
bands are observed on the gel confirming that the siRNA is stable and protected by the 271 
lipoplexes during the freeze-drying process. Same observations were done for lipoplexes with 272 
DSPE-PEG750 and with ceramide-PEG2000.  273 
The same results were obtained after 25 days of storage at 4°C (figure 4.B). This experiment 274 
confirms that the storage at 4°C during 25 days has no deleterious effect on the siRNA. 275 
Moreover, in another study, we have shown with active siRNA that the freeze-drying process 276 
allows to keep the gene-silencing properties of siRNA (results not shown). The storage stability 277 
is one of the key challenges for a safe translation to the clinic and all these results indicate that 278 
pegylated lipoplexes freeze-dried with 1% of trehalose keep their characteristics during at least 279 
25 days.  280 
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 281 
Figure 4: Complexation efficiency of pegylated lipoplexes evaluated by agarose gel 282 
electrophoresis. (A) Day 0. siRNA: control with free siRNA. 1: lipoplexes before freeze-drying. 283 
2: lipoplexes after freeze-drying. 2+Trit.: lipoplexes after freeze-drying and with 0.5% w/v of 284 
Triton X-100. Conditions 1, 2 and 2+Trit. were performed on lipoplexes with DSPE-PEG2000, 285 
DSPE-PEG750 and ceramide-PEG2000. (B) Same conditions after 25 days of storage at 4°C.  286 
 287 
3.2. Behaviour of lipoplexes in artificial vaginal mucus  288 
3.2.1. Diffusion and size of the lipoplexes 289 
To reach the epithelial tissue, lipoplexes have to diffuse through the vaginal mucus. fSPT was 290 
used to estimate the mobility of lipoplexes in undiluted artificial vaginal fluids and to monitor 291 
their aggregation. fSPT technique makes use of videos of diffusing fluorescently labelled 292 
particles to analyse their individual motion trajectory in complex biological media and 293 
calculates their individual diffusion coefficient (D, µm2/s). In case of freely diffusing particles, 294 
the D distribution so obtained is converted into a size distribution (nm) by using the Stokes-295 
Einstein equation, as previously described [26, 34, 35]. 296 
Fluorescently labelled lipoplexes were incubated in RNAse free water, as a control, and in 297 
undiluted simulated vaginal fluids (SVF), both at 37°C. The movement of all individual lipoplexe 298 
was tracked and registered. From the analysis of the recorded trajectories, the diffusion 299 
coefficients (µm2/s) were calculated in order to compare the diffusion ability of the different 300 
types of lipoplexes inside vaginal mucus.  301 
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Due to the complex ethical and practical procedures to obtain human vaginal fluids (limited 302 
quantity, stability and storage), SVF has been used as a model instead of natural mucus. It 303 
has similar viscosity, pH and osmolality to that of physiological fluids and mucus and thus 304 
should to a high extent resemble the human vaginal mucus [24]. 305 
As demonstrates in figure 5.A, the lipoplexes were able to freely diffuse in RNAse free water. 306 
The peak values of the diffusion distributions varied from 0.7 µm2/s for the lipoplexes with 307 
DSPE-PEG750 to 1.3 µm2/s for unpegylated lipoplexes. In SVF (figure 5.B), the lipoplexes are 308 
still able to diffuse, but slower than in water. This difference of diffusion is highly likely ascribed 309 
to the viscosity of SVF (~ 3 mPa.s) and its complex composition. In SVF, lipoplexes have to 310 
pass through the different components of mucus and particularly through the crosslinked mucin 311 
fibres, which form a highly heterogeneous mesh. These results underline also the necessity to 312 
measure the diffusion directly in the relevant biofluids rather than in diluted fluids. Despite the 313 
mucus barrier, lipoplexes are still capable to diffuse. Concerning the influence of the type of 314 
PEG on the diffusion, figure 5.B shows that lipoplexes with DPSE-PEG2000 and ceramide-315 
PEG2000 are able to diffuse faster than those without PEG and with DSPE-PEG750. This small 316 
difference could be due to the difference of the PEG length. Coating lipoplexes with PEG2000 317 
could further minimize adhesive interactions between nanoparticles and mucus constituents, 318 
compared to PEG750 and without PEG, decreasing aggregation phenomenon and slightly 319 
increasing the diffusion.  320 
 321 
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 322 
Figure 5: Diffusion distributions of lipoplexes without PEG and with DSPE-PEG2000, DSPE-323 
PEG750 or ceramide-PEG2000 following incubation at 37°C in RNAse free water (A) and in SVF 324 
(B), determined by fSPT analysis.  325 
 326 
In order to verify this hypothesis, the size of the lipoplexes was estimated in SVF compared to 327 
water. Although the Dynamic Light Scattering (DLS) is the most common technique for 328 
measuring particle size in aqueous media, it is difficult to directly measure the size in undiluted 329 
biological fluids by this technique. Therefore, fSPT was used and size distributions of the 330 
lipoplexes in SVF were obtained. In water (figure 6.A), mean values between 170 - 230 nm 331 
were observed for all the lipoplexes, PEG or not. These results are in good agreement with 332 
those obtained previously by DLS (section 3.1.2.). In SVF (figure 6.B), only the lipoplexes with 333 
DSPE-PEG2000 remain stable and keep their initial size close to 200 nm with a narrow 334 
distribution. The lipoplexes with ceramide-PEG2000 show a slight aggregation represented by 335 
a shift of the distribution compared to the size distribution in water. For the lipoplexes with 336 
DSPE-PEG750 and without PEG, the aggregation was more pronounced as particles with a 337 
diameter ranging from 300 to 500 nm were measured.  338 
The size distributions outcomes confirm our hypothesis: coating lipoplexes with PEG2000 can 339 
minimize adhesive interactions between nanoparticles and mucus constituents, compared to 340 
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PEG750 and without PEG, decreasing aggregation phenomenon and slightly increasing the 341 
diffusion. The data stand in line with another previous study by J. das Neves et al [25].  342 
Moreover, it is well known that the size is a major requirement for an optimal vaginal diffusion 343 
and it has been demonstrated that particles with a diameter around 200 to 300 nm show the 344 
best diffusive property contrarily to particles with a diameter higher than 500 nm [27, 30].  345 
 346 
 347 
Figure 6: fSPT sizing of lipoplexes without PEG and with DSPE-PEG2000, DSPE-PEG750 or 348 
ceramide-PEG2000 following incubation at 37°C in RNAse free water (A) and in SVF (B).  349 
 350 
3.2.2. Release of the siRNA  351 
The release of siRNA from lipoplexes was evaluated using Fluorescence Correlation 352 
Spectroscopy (FCS). FCS is a technique used to calculate the percentage of complexed fluo-353 
siRNA by the lipoplexes and to follow its release as a function of time, as described previously 354 
[36-39]. This technique monitors the fluorescence intensity fluctuations of molecules diffusing 355 
in and out the focal volume of a confocal microscope. When free siRNA is present in the focal 356 
volume, a fluorescence signal (baseline) proportional to the siRNA concentration is obtained. 357 
Contrariwise, when the siRNA is complexed within the nanoparticles, the concentration of free 358 
siRNA decreases (the baseline decreases also) and peaks with high fluorescence intensity 359 
appear each time a particle passes in the detection volume. Conversely, when the siRNA is 360 
dissociated from the lipoplexes, the concentration of free siRNA increases resulting in an 361 
increase of the baseline [37]. 362 
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In RNAse free water (figure 7.A), the initial percentage of incorporation was high (more than 363 
95%) for all the lipoplexes. These results are in accordance with those obtained previously, by 364 
another quantification technique (Quant-iTTM RiboGreen® RNA assay) [23]. After 4 hours, the 365 
overall siRNA released was limited to maximally 10%. In SVF (figure 7.B), no further release 366 
was observed and a very slight difference can be noticed between the studied lipoplexes, those 367 
with DSPE-PEG2000 retained the totality of complexed siRNA even after 4 hours in SVF. To 368 
reach the cytoplasm of targeted cells, the siRNA must be kept intact in the lipoplexes. The 369 
lipoplexes have to protect it from the mucus components to avoid its degradation. They have 370 
to diffuse into the mucus to reach the targeted cells and release their content only once in the 371 
cytoplasm of these cells reached. The low release of siRNA observed by FCS indicates that 372 
lipoplexes pegylated or not, are stable for at least 4 hours in SVF at 37°C.  373 
 374 
 375 
Figure 7: Percentage of complexed siRNA into lipoplexes according to the time in RNAse free 376 
water (A) and in SVF (B), determined by FCS analysis (n=3).  377 
 378 
In view of the colloidal stability results in both water and SVF (3.1. and 3.2. sections), lipoplexes 379 
grafted with DSPE-PEG2000 seem the most colloidally stable from the all formulations, and 380 
hence were selected for further hydrogel/sponge formulation.  381 
 382 
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3.3. Lipoplexes effect on the characteristics of the sponges  383 
Placebo sponges, with different amounts of polymer (HEC) and plasticizer (PEG) were 384 
previously characterized [19]. As the polymer concentration directly influences the viscosity 385 
and probably the diffusion of lipoplexes, two concentrations of HEC were tested (0.83% and 386 
1.67%). Moreover, the effect of the lipoplexes on the sponge’s characteristics (mucoadhesion, 387 
hardness, deformability and morphology) was also investigated.  388 
3.3.1. Mucoadhesion 389 
HEC polymer has been chosen to prepare the sponges for its well-described mucoadhesive 390 
properties [22]. It has the possibility to anchor the formulation in the administration site and 391 
allows a prolonged delivery of the incorporated material, thereby maximizing the clinical 392 
performance [40]. Moreover, this polymer is considered as a non-toxic and non-irritating 393 
material. Thanks to its biocompatible property, it has been employed in several commercialized 394 
products intended for a vaginal use [4, 18, 41].  395 
In this section, the ability of the sponges to adhere to a partially hydrated mucin disc, mimicking 396 
vaginal conditions, was studied. The mucoadhesive strength (N) was determined by the force 397 
required to separate the disc from the sponge. Figure 8 shows the mucoadhesion of the 398 
placebo sponges, of the sponges containing 1% trehalose and of the sponges containing both 399 
1% trehalose and lipoplexes, in comparison with different vaginal commercialized products. All 400 
the selected commercialized forms are gels (Lubrilan®, Mithra Intim gel®, Lubexxx®, Crinone®), 401 
creams (Gynodaktarin®, Gynoxin®, Canestene®) or a solid system (Preventex®) and are not 402 
specifically intended to be adhesive. They have been chosen to have an idea of their 403 
mucoadhesive capacity, as no reference product and no reference values of mucoadhesion 404 
are available. 405 
It is obvious that all the sponges are significantly more mucoadhesive than the pharmaceutical 406 
products, even at the smallest concentration of HEC (0.83%). Moreover, as demonstrated 407 
before, the concentration of HEC influences the mucoadhesion [19]; sponges with 1.67% HEC 408 
are more adhesive (~ 1.1 N) than sponges with 0.83% (~ 0.7 N) and this can be explained by 409 
the interpenetration mechanism involved in the mucoadhesive interactions [42]. Indeed, the 410 
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intimate contact between the two surfaces, sponge and mucin disc, induces interpenetration 411 
of glycoproteins chains of mucin with polymeric chains of HEC. Assuming that the surface of 412 
the mucin disc in each experiment is similar, the higher the HEC concentration is, the stronger 413 
the mucoadhesive bonds are. Finally, the presence of trehalose and lipoplexes has no 414 
significant influence (p > 0.05) on the mucoadhesion force. Lipoplexes in the sponges do not 415 
influence their mucoadhesion capacity.  416 
 417 
 418 
Figure 8: Adhesion force (N) of placebo sponges (1) - (4), of sponges with 1% trehalose (2) - 419 
(5) and of sponges with 1% trehalose and lipoplexes (3) - (6) compared to pharmaceutical 420 
commercial products. Results are analyzed by a one-way ANOVA, followed by a Dunnett’s 421 
test (n=6). 422 
 423 
3.3.2. Hardness and deformability 424 
Topical application of sponges requires an insight to their behaviour after compression 425 
stresses. These systems should possess suitable mechanical resistance to facilitate the 426 
application inside vagina and also enough resistance to deformation to ensure durability 427 
against shear stress encountered. The hardness is directly correlated with the polymer 428 
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concentration (figure 9.A); sponges with 1.67% are harder than sponges with 0.83% HEC (~ 1 429 
N vs ~ 0.7 N). Moreover, the presence of trehalose and lipoplexes has no significant influence 430 
(p > 0.05) on this characteristic. Since there are no reference values for optimal hardness, the 431 
ability of sponges to be easily removed out of their containers and their malleability were also 432 
analysed. Indeed, all sponges met these conditions; they are hard enough to be extracted 433 
without being broken, they are malleable and retain their shape. Regarding the deformability 434 
(figure 9.B), the slopes of the curves provide information about the deformability of sponges. 435 
An increase in the slope corresponds to an increase deformability of the sponge. Specifically, 436 
the sponges with 1.67% show around 10% of deformability while those containing 0.83% are 437 
deformed at maximum 20%. Again, the presence of trehalose and lipoplexes does not change 438 
the deformability.  439 
 440 
 441 
Figure 9: (A) Hardness (N) and (B) deformability (%) of placebo sponges (1) - (4), of sponges 442 
with 1% trehalose (2) - (5) and of sponges with 1% trehalose and lipoplexes (3) - (6). One-way 443 
ANOVA, followed by the Dunnett’s test is used (n=12).  444 
 445 
3.3.3. Morphology  446 
The morphology and integrity of lipoplexes in sponges were evaluated by SEM analysis. As 447 
demonstrated in figure 10, placebo sponges (A and B) and sponges with 1% trehalose (C and 448 
D) have smooth surfaces, without any irregularities and/or pores. On the contrary, sponges 449 
with lipoplexes (E, F and G) show a rough surface, with small individual spherical asperities. 450 
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Their size is around 250 nm, in agreement with the sizes obtained using DLS and fSPT in the 451 
previous sections (3.1.2. and 3.2.1.). In order to demonstrate that these spherical asperities 452 
correspond to intact lipoplexes, an elemental analyse was performed. This technique was used 453 
to confirm the presence of the phosphorous atom (P) and thus the presence of the siRNA in 454 
the observed vesicles. Figure 11 shows that the P atom was detected in the sponge containing 455 
1.67% HEC, 1% trehalose and lipoplexes (same results were observed for sponges with 0.83% 456 
HEC while no P detection was observed with placebo sponges, data not shown). This confirms 457 
that observed vesicles are lipoplexes. After being incorporated into the hydrogel and freeze-458 
dried, the lipoplexes retain their morphology, are intact and still have a size between 200 to 459 
300 nm. 460 
 461 
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 462 
Figure 10: SEM images of sponges with 1.67% HEC. (A) - (B) are placebo sponges, (C) - (D) 463 
are sponge with 1% trehalose and (E) - (F) - (G) are sponges containing 1% trehalose and 464 
lipoplexes.  465 
 466 
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 467 
Figure 11: (A) SEM image and (B) phosphorous (P) elemental analysis (SEM-EDX) on sponge 468 
containing 1.67% HEC, 1% trehalose and lipoplexes.  469 
 470 
3.4. Diffusion and stability of lipoplexes in rehydrated sponges 471 
When applied in the vagina, sponges have to rehydrate with mucus to form a hydrogel. 472 
Lipoplexes will have to progressively diffuse through the gel and then through the vaginal 473 
mucus to reach vaginal epithelium. Therefore it is necessary to determine the diffusion ability 474 
of lipoplexes and their stability into the rehydrated sponges. Moreover, the influence of HEC 475 
concentration was also studied. fSPT and FCS techniques, as described previously, were used 476 
for these analyses. Sponges were rehydrated with SVF at 37°C, mimicking vaginal conditions. 477 
As shown in figure 12.A, lipoplexes have different diffusion profiles in the two types of gels 478 
(0.83% vs 1.67 % HEC). In gels with 0.83% HEC, there are two populations of particles: a 479 
large majority with a high peak value (D ~ 0.8 µm2/s) and some others particles with a lower 480 
peak value of the diffusion distribution (D ~ 0.2 µm2/s). Regarding the measured sizes of these 481 
lipoplexes, there are also two populations; a large majority with a diameter at around 200 nm 482 
and also a little fraction of particles with a peak diameter around 90 nm (data not shown). 483 
Indeed, particles with a diameter around 200 - 300 nm can better diffuse in mucus than smaller 484 
with a diameter below 100 nm [16]. Lipoplexes are also able to diffuse in gels with 1.67% HEC 485 
but slower than in the 0.83% HEC gels (D ~ 0.4 µm2/s). The difference in viscosity of the two 486 
hydrogels before and after freeze drying can explain this (100 mPa.s for the 0.83% HEC 487 
hydrogel and 1300 mPa.s. for the 1.67% HEC hydrogel). Moreover, sponges were rehydrated 488 
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with SVF which also increases the viscosity of the final hydrogel. This can consequently further 489 
reduce the mobility of lipoplexes.  490 
The stability of lipoplexes (siRNA release) in the hydrogel (figure 12.B) was next assessed. 491 
Within both types of rehydrated sponges, maximum 8% of siRNA are released after 4 hours at 492 
37°C. The concentration of HEC does not influence the entrapment efficiency of lipoplexes. 493 
They diffuse through rehydrated sponges without releasing their content. 494 
 495 
 496 
Figure 12: Diffusion distributions of lipoplexes (A) and percentage of complexed siRNA as a 497 
function of time (B) in 0.83% and 1.67% HEC sponges; respectively determined by fSPT and 498 
FCS analysis (n=3). 499 
 500 
3.5. Release of lipoplexes outside rehydrated sponges 501 
Finally, the release rate of lipoplexes from rehydrated sponges was monitored over time and 502 
compared for both types of sponges (0.83% vs 1.67% HEC). By employing fSPT, videos were 503 
recorded in order to demonstrate the presence of lipoplexes in the acceptor compartment filled 504 
with SVF and consequently their diffusion outside the rehydrated system (see on figure 1). 505 
Figure 13 represents screenshots of these videos (A=1.67% and B=0.83% HEC). This 506 
qualitative technique is used to show the number of lipoplexes diffusing in the mucus and if it 507 
increases with time.  508 
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It is first observed that no lipoplexes were in the acceptor compartment at time 0, independently 509 
of the HEC concentration. A lag time is necessary for the rehydration of sponges and to allow 510 
the diffusion of lipoplexes. Then, fluorescent spots appear progressively in the acceptor 511 
compartment with a delay difference of 2 hours between the two sponges. Lipoplexes appear 512 
in the acceptor compartment after two hours for 0.83% HEC sponges (B) while they appeared 513 
after four hours for 1.67% HEC sponges (A). These spots confirm that lipoplexes are able to 514 
diffuse through sponges rehydrated with artificial vaginal fluids (section 3.4.). The appearance 515 
delay of lipoplexes in the receiving compartment depends on the HEC concentration; the 516 
higher the concentration of HEC, the longer the rehydration duration of the sponges. Moreover, 517 
increasing the concentration of HEC results in gels with higher viscosity values. These two 518 
phenomena delay the diffusion of the lipoplexes in the gel and in the receiving compartment.  519 
Despite the different viscosities, lipoplexes were able in both cases to diffuse from the 520 
rehydrated sponges even after 6 hours at 37°C. The increased amount of fluorescent spots 521 
suggests an increase of lipoplexes release. This last point demonstrates that the sponges can 522 
be considered as a matrix system allowing a sustained delivery of lipoplexes.  523 
 524 
 525 
Figure 13: Screenshots of fSPT videos of SVF in the acceptor compartment after rehydration 526 
of sponges with 1.67% HEC (A) or with 0.83% HEC (B) and lipoplexes.   527 
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4. Conclusions  528 
This study shows the feasibility of entrapping pegylated lipoplexes into a solid matrix system 529 
for a prolonged delivery of siRNA in vaginal mucus. The sponge system is obtained by freeze-530 
drying and is intended to be administered directly inside vagina in order to treat pathologies 531 
using the gene silencing mechanism. For this, the sponges have to be in situ rehydrated to 532 
form a hydrogel and allow a sustained release of lipoplexes. Hydroxyethyl-cellulose (HEC) was 533 
chosen to prepare the sponges for its mucoadhesive properties. 534 
Vaginal administration of lipoplexes is a challenge since the mucus presents a significant 535 
barrier to effective delivery. To overcome this, 30% of three types of PEG derivatives were 536 
grafted on the lipoplexes; DSPE-PEG2000, DSPE-PEG750 and ceramide-PEG2000. Their 537 
physicochemical characteristics, colloidal stability and their ability to diffuse inside simulated 538 
vaginal fluids (SVF) were tested. Altogether, lipoplexes with DSPE-PEG2000 are the best choice 539 
for the intended application. They have a size close to 200 nm, which is adequate for 540 
mucopenetration. They are stable after freeze-drying and have high complexation efficiency 541 
(> 95%). They have the highest diffusion coefficient and do not aggregate in SVF. Moreover, 542 
they do not release their content even after 4 hours at 37°C. Consequently, lipoplexes with 543 
DSPE-PEG2000 were chosen for incorporation inside HEC hydrogels/sponges.  544 
In order to be administered into the vagina and to ensure a prolonged delivery of the lipoplexes, 545 
the sponges must meet acceptable mechanical characteristics such as ease of manipulation, 546 
low hardness and good bioadhesion. Furthermore, lipoplexes have to be intact inside the 547 
sponges. As our analysis shows, the sponges containing lipoplexes meet these criteria. 548 
Sponges are hard enough to be malleable and flexible; what is important for an easy 549 
application. The maximum percentage of deformation is around 20%, which could be enough 550 
to resist to shear stress inside vagina. The strength necessary to separate the hydrated mucin 551 
disc from the surface of the sponge is almost 0.7 N which is higher than for commercialized 552 
vaginal products and could be sufficient to obtain an appropriate retention during the 553 
therapeutic period. In addition, lipoplexes, incorporated in sponges, retain their morphology 554 
and their original size.  555 
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To mimic vaginal conditions, sponges were rehydrated with SVF. The diffusion of lipoplexes 556 
inside and outside the rehydrated sponges was measured. Depending on the HEC 557 
concentration, lipoplexes present two different diffusion profiles. The diffusion is slower in the 558 
sponges containing 1.67% of HEC than in those containing 0.83% of HEC. This observation is 559 
the same for the diffusion outside the system. The release rate is lower in the 1.67% HEC 560 
sponges. This can be explained by the fact that sponges with higher quantities of HEC need 561 
more time to be rehydrated and that they have a higher viscosity after in situ rehydration. These 562 
two phenomena delay the diffusion of the lipoplexes inside the gel and in the receiving 563 
compartment. Considering that it takes 4 hours for lipoplexes to diffuse outside rehydrated 564 
sponge with 1.67%, the sponges containing 0.83% HEC should be more suited for an optimal 565 
vaginal treatment.  566 
In conclusion, a new mucoadhesive solid system adapted for a prolonged vaginal delivery of 567 
lipoplexes has been developed. It is easy to handle, able to protect pegylated lipoplexes and 568 
to be rehydrated with vaginal fluids. In future studies, this promising freeze-dried 569 
mucoadhesive sustained released system will be validated with active siRNA. 570 
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